# PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/pa-23-230-phs-2023-2-omnibus-solicitation-of-the-nih/  
Official notice: https://www.grants.gov/search-results-detail/349223

> National Institutes of Health offered grants to small businesses. Applications closed on April 5, 2024.

| Field | Value |
|---|---|
| Opportunity number | PA-23-230 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | April 5, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.084, 93.173, 93.286, 93.846, 93.855, 93.859, 93.866 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

## Questions people ask

### Is PA-23-230 still open?

No. It closed on April 5, 2024.

### Who can apply for PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?

Closed April 5, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under PA-23-230?

NIH RePORTER lists 599 projects funded under PA-23-230 in fiscal 2024 to 2026, at 543 institutions. The most were at 3DT Holdings, LLC, Syntis Bio Inc, Revel Pharmaceuticals Inc.

### Who has won Prevention of Disease, Disability, and Death by Infectious Diseases   grants before?

The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.